MCTC Holdings Launches Delivery System Development Program for TCH-V
Goal is to increase bioavailability of rare cannabinoid.
MCTC Holdings, Inc. has undertaken Project Varin, a program to develop new delivery systems for tetrahydrocannabivarin (THC-V), a rare cannabinoid found in Cannabis sativa purported to suppress appetite.
"THC-V is so rare and difficult to obtain, it is currently valued at around $500,000 per kilogram, which is approximately ten times the price of gold,” said Arman Tabatabaei, CEO of MCTC Holdings, Inc. “ In order for the marketplace to utilize this potentially beneficial exotic cannabinoid, new delivery systems will need to be developed to allow the amount of THC-V administered to be efficiently utilized by the human body. This issue of bioavailability has been a significant ongoing concern for the industry relative to many cannabinoids, but with the rarity of THC-V, the need for efficient delivery is hugely amplified. It is our goal to solve this pressing industry issue. Based on our already completed laboratory accomplishments and our patent-pending technologies, we believe this goal is within our reach."
The primary goal of this groundbreaking research by MCTC will be to develop THC-V delivery methods that significantly improve bioavailability. In the first stage of the program, researchers plan to produce THC-V polymeric nanoparticles and nanofibers based on the company's patent-pending technologies.
Over the past few months, MCTC has seen success in producing cannabidiol (CBD) particles, which the company's researchers believe is highly leverageable relative to THC-V particle creation. In the second phase of development, which is scheduled to begin in March 2020, the company plans to apply its ongoing cannabinoid glycosides research to THC-V, in order to produce THC-V with unparalleled levels of availability at minimal usage levels.
"Interest in THC-V and cannabinol (CBN) is quickly growing within the cannabinoid industry, and we believe both will be important topics throughout 2020 and beyond,” Tabatabaei said. “With the recent availability of nearly 100 percent pure research quantities of these exotic cannabinoids now hitting the marketplace and the peaking interest, we believe our timing in launching Project Varin is optimal. We have made great strides in only a few months relative to cannabinoid research. We plan to apply what we have learned and our new patent-pending technologies to THC-V and eventually to CBN."
MCTC has recently filed five patents on hemp extract technologies and delivery systems. The company is currently working with patent counsel to protect various other aspects of its other new technologies. As previously announced, the company plans to continue other areas of delivery systems research including its programs pertaining to cannabinoid glycosides, polymeric cannabinoid nanoparticles and nanofibers, and its hemp extract-based alcohol replacement technologies.